Cerus Corporation shares rise 1.63% after-hours following regulatory approvals for INT200.

Cerus Corporation rose 1.63% in after-hours trading, with the company announcing two in-country regulatory approvals for INT200, one by the French National Agency for Medicines and Health Product Safety (ANSM) and the other by the Swiss Agency for Therapeutic Products (Swissmedic). The INT200, the Company's next generation LED-based illumination device, was developed as the new foundational platform for the INTERCEPT Blood System, with input and feedback from global customers to enhance daily blood center operations.